Don't stop at statins: complementary PCSK9 use in patients at high risk for recurrent cardiac events
Eur Heart J Qual Care Clin Outcomes
.
2019 Jul 1;5(3):193-194.
doi: 10.1093/ehjqcco/qcz013.
Authors
Anna Grodzinsky
1
,
Yashashawi Pokharel
1
,
Rahul Myadam
1
Affiliation
1
Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, 9th Floor CV Research, 4401 Wornall Road, Kansas City, MO, USA.
PMID:
30882136
DOI:
10.1093/ehjqcco/qcz013
No abstract available
Publication types
Comment
MeSH terms
Cardiovascular Diseases*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Proprotein Convertase 9
Sweden
Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 protein, human
Proprotein Convertase 9